Cancer metastasis therapeutic targets and drug discovery: Emerging small-molecule protein kinase inhibitors

Expert Opinion on Investigational Drugs

Volumn 13, Issue 1, 2004, Pages 1-19

  Sawyer, Tomi K ^a  

^a ARIAD PHARMACEUTICALS INC   (United States)

Author keywords

Angiogenesis; Apoptosis; Bisphosphonates; Bone metastasis; CDK; E cadherin; EGF R; Focal adhesion kinase; IGF R; Integrin receptor; Integrin linked kinase; Mammalian target of rapamycin; MAPK; Metastasis suppresor genes; MMP; NF kB; P13K; Protein kinase; Ras farnesyl protein transferase; Signal transduction inhibition; Src; Tumour suppressor genes; VEGF R

Indexed keywords

3 DIMETHYLAMINO 1 PHENYL 6 PYRIDAZONE; 4 AMINO 7 TERT BUTYL 5 (4 METHYLPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; 6 (2,6 DICHLOROPHENYL) 2 (4 FLUORO 3 METHYLANILINO) 8 METHYL 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; [4 [2 CYCLOPENTYL 9 (3 HYDROXYPHENETHYL)PURIN 6 YLAMINO]PHENYL]DIMETHYLPHOSPHINE OXIDE; AMZ 475271; ANGIOSTATIN; ANTINEOPLASTIC AGENT; AP 23451; BISPHOSPHONIC ACID DERIVATIVE; BMS 27291; BOSUTINIB; CGP 76030; CLODRONIC ACID; ENDOSTATIN; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; FOCAL ADHESION KINASE; GEFITINIB; IMATINIB; INTEGRIN RECEPTOR; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; PAMIDRONIC ACID; PROTEIN KINASE INHIBITOR; RAF PROTEIN; RAS PROTEIN; RISEDRONIC ACID; TANOMASTAT; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZOLEDRONIC ACID;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BONE METASTASIS; BREAST METASTASIS; CANCER GROWTH; CANCER INVASION; CANCER LOCALIZATION; CANCER RESEARCH; CANCER SURVIVAL; CYTOLOGY; DRUG DESIGN; DRUG EFFICACY; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; GENE FUNCTION; GENE MAPPING; GENETIC SCREENING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; METASTASIS; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; ONCOGENE SRC; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; TUMOR VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; MOLECULAR STRUCTURE; NEOPLASM METASTASIS; NEOPLASMS; PROTEIN KINASE INHIBITORS;

EID: 1642555578     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.13.1.1     Document Type: Review

References (211)

1. BOGENRIEDER T, HERLYN M: Axis of evil: molecular mechanisms of cancer metastasis. Oncogene (2003) 22:6524-6536.
2. HANAHAN D, WEINBERG RA: The hallmarks of cancer. Cell (2000) 100:57-70.
3. MACALUSO M, PAGGI MG, GIORDANO A: Genetic and epigenetic alterations as hallmarks of the intricate road to cancer. Oncogene (2003) 22:6472-6478.
4. PONDER BAJ: Cancer genetics. Nature (2001) 411:336-341.
5. NYGREN P, LARSSON R: Overview of the clinical efficacy of investigational anticancer drugs. J. Internal Med. (2003) 251:46-75.
6. CHAMBERS AF, GROOM AC, MACDONALD IC: Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer (2002) 2:563-572.
7. KAUFFMAN EC, ROBINSON VL, STADLER WM, SOKOLOFF MH, RINKER-SCHAEFFER CW: Metastases suppression: the evolving role of metastases suppressor genes for regulating cancer cell growth at the secondary site. J. Urology (2003) 169:1122-1133.
8. WOODHOUSE EC, CHUAQUI RF, LIOTTA LA: General mechanisms of metastasis. Cancer (1997) 80:1529-1537.
9. FIDLER LJ: Critical determinants of cancer metastasis: rational for therapy. Cancer Chemother. Pharmacol. (1999) 43:S3-S10.
10. WYCKOFF JB, JONES JG, CONDEELIS JS, SEGALL JE: A critical step in metastasis: in vivo analysis of intravasation at the primary tumor. Cancer Res. (2000) 60:2504-2511.
11. FIDLER LJ: Orthotopic implantation of human colon carcinomas into nude mice provides valuable model for the biology and therapy of metastasis. Cancer Metastasis Rev. (1991) 15:272-306.
12. KOHN EC, LIOTTA LA. Molecular insights into cancer invasion: strategies for prevention and intervention. Cancer Res. (1995) 55:1856-1862.
13. RADINSKY R, ELLIS LM: Molecular determinants in the biology of liver metastasis. Surg. Oncol. Clin. North Am. (1996) 5:215-229.
14. MUNDY GR: Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer (2002) 2:584-593.
15. HOFFMAN RM: Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Invest. New Drugs (1999) 17:343-359.
16. CHAMBERS AF, MACDONALD IC, SCHMIDT EE, MORRIS VL, GROOM AC: Clinical targets for antimetastasis therapy. Adv. Cancer Res. (2000) 79:91-121.
17. THOMAS SM, BRUGGE JS: Cellular functions regulated by Src family kinases. Ann. Rev. Cell Dev. Biol. (1997) 13:513-609.
18. BLUME-JENSEN P, HUNTER T: Oncogenic kinase signalling. Nature (2002) 411:355-365.
19. DONG JT, LAMB PW, RINKER-SCHAEFFER CW et al.: KAI1, a metastasis suppressor gene for prostate cancer on human chromasome 11p11.2. Science (1995) 12:884-886.
20. MORRIS VL, SCHMIDT EE, KOOP S et al.: Effects of the disintegrin erisostatin on individual steps of hematogeneous metastasis. Exp. Cell Res. (1995) 219:571-578.
21. HERYNK MH, RADINKSKY R: The coordinated functional expression of epidermal growth factor receptor and c-Met in colorectal carcinoma metastasis. In Vivo (2000) 14:587-596.
22. DE MARZO AM, KNUDSEN B, CHAN-TACK K, EPSTEIN JI: E-cadherin expression as a marker of tumor aggressiveness in routinely processed radical prostatectomy specimens. Urology (1999) 3:707-713.
23. GAO AC, LOU W, DONG JT, ISAACS JT: CD44 is a metastasis suppressor gene for prostatic cancer located on human chromosome 11p13. Cancer Res. (1997) 57:846-849.
24. YOSHIDA BA, DUBAUSKAS Z, CHEKMAREVA MA, CHRISTIANO TR, STADLER WM, RINDKER-SCHAFFER CW: Mitogen-activated protein protein 4/stress-activated protein/Erc kinase 1 (MKK4/SEK1), a prostate cancer metastasis suppressor gene encoded by human chromosome 17. Cancer Res. (1999) 59:5483-5487.
25. KONISHI N, NAKAOKA S, TSUZUKI T et al.: Expression of nm23-H1 and nm23-H2 proteins in prostate carcinoma. Jpn. J. Cancer Res. (1993) 84:1050-1054.
26. LEE JH, WELCH DR: Suppression of metastasis in human breast carcinoma MDA-MB-435 cells after transfection with the metastasis suppressor gene, KiSS-1. Cancer Res. (1997) 57:2384-2387.
27. LEE JH, MIELE ME, HICKS DJ et al.: KiSS-1, a novel human malignant melanoma metastasis-suppressor gene. J. Natl. Cancer Inst. (1996) 88:1731-1777.
28. HABERMANN H, RAY V, HABERMANN W, PRINS GS: Alterations in gap junction protein expression I human benign prostatic hyperplasia and prostate cancer. J. Urol. (2002) 167:655-660.
29. NAUMOV GN, WILSON SM, MACDONALD IC et al.: Cellular expression of green fluorescent protein, coupled with high-resolution in vivo videomicroscopy to monitor steps in tumor metastasis. J. Cell Sci. (1999) 112:1835-1842.
30. KUO TH, KUBOTA T, WATANABE M et al.: Liver colonization competence governs colon cancer metastases. Proc. Natl. Acad. Sci. USA (1995) 92:12085-12099.
31. HAHN WC, WEINBERG RA: Modelling the molecular circuitry of cancer. Nat. Rev. Cancer (2002) 2:331-341.
32. NAM NH, PARANG K: Current targets for anticancer drug discovery. Curr. Drug Targets (2003) 4:159-179.
33. 2+-binding protein family. Gene Dev. (1989) 3:1086-1093.
34. DEAR TN, RAMSHAW IA, KEFFORD RF: Differential expression of a novel gene, WDNM1, in nonmetastatic rat mammary adenocarcinoma cells. Cancer Res. (1988) 48:5203-5209.
35. DEAR TN, MCDONALD DA, KEFFORD RF: Transcriptional down-regulation of a rat gene, WDNM2, in metastatic DMBA-8 cells. Cancer Res. (1989) 49:5323-5328.
36. BASSETT P, BELLOCQ JP, WOLF C et al.: A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinoma. Nature (1990) 348:699-704.
37. FUJITA M, SPRAY DC, CHOI H et al.: Extracellular matrix regulation of cell - cell communication and tissue-specific gene expression in primary liver cultures. Prog. Clin. Biol. Res. (1986) 226:333-360.
38. XIA W, UNGER P, MILLER L, NELSON J, GELMAN IH: The Src-suppressed C kinase substrate SSeCKS, is a potential metastasis inhibitor in prostate cancer. Cancer Res. (2001) 61:5644-5651.
39. MIYAKE M, INUFASA H, ADACHI M et al.: Suppression of pulmonary metastasis using adenovirally motility related protein-1 (MRP-1/CD9) gene delivery. Oncogene (2000) 19:5221-5226.
40. RADFOR KJ, MALLESCH J, HERSEY P: Suppression of human melanoma cell growth and metastasis by the melanoma associated antigen CD63 (ME491). Int. J. Cancer (1995) 62:631-635.
41. NAKAGAWA T, TANAKA S, SUZUKI H et al.: Overexpression of the csk gene suppresses tumor metastasis in vivo. Int. J. Cancer (2000) 88:384-391.
42. FU Z, SMITH PC, ZHANG L et al.: Effects of Raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. J. Natl. Cancer Inst. (2003) 95:878-889.
43. BISCARDI JS, TICE DA, PARSON SJ: c-Src, receptor tyrosine kinases, and human cancer. Adv. Cancer Res. (1999) 76:61-119.
44. SCHLESSINGER J: New roles for Src kinases in control of cell survival and angiogensis. Cell (2000) 100:293-296.
45. FRAME MC: Src in cancer: deregulation and consequences for cell behaviour. Biochim. Biophys. Acta (2002) 1602:114-130.
46. c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. J. Clin. Invest. (1992) 90:1622-1627.
47. XING L, VENGAS AM, CHEN A et al.: Genetic evidence for a role for Src family kinases in TNF family receptor signaling and cell survival. Genes Dev. (2001) 15:241-253.
48. PERL AK, WILGENBUS P, DAHL U, SEMB H, CHRISTOFORI G: A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature (1998) 392:190-193.
49. PAUL R, EWING CM, JARRARD DF, ISAACS WB: The cadherin cell-cell adhesion pathway in prostate cancer progression. Br. J. Urol. (1997) 79(Suppl.):37-43.
50. MBALAVIELE G, DUNSTAN CR, SASAKI A, WILLIAMS PJ, MUNDY GR, YONEDA T: E-cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastasis in an experimental metastasis model. Cancer Res. (1996) 56:4063-4070
51. DARNELL JE JR: Transcription factors as targets for cancer therapy. Nat. Rev. Cancer (2002) 10:740-749.
52. CLARK EA, GOLUB TR, LANDER ES, HYNES RO: Genomic analysis of metastasis reveals an essential role for RhoC. Nature (2000) 406:532-535.
53. AVIZIENYTE E, WYKE AW, JONES RJ et al.: Src-induced de-regulation of E-cadherin in colon cancer cells requires integrin signalling. Nat. Cell Biol. (2002) 8:632-638.
54. SAKAMOTO M, TAKAMURI M, INO Y, MIURU A, GENDA T, HIROHASHI S: Involvement of c-Src in carcinoma cell motility and metastasis. Jpn. J. Cancer Res. (2001) 92:941-946.
55. BOYER B, BOURGEOIS Y, POUPON M-R: Src kinase contributes to the metastatic spread of carcinoma cells. Oncogene (2002) 21:2347-2356.
56. HOOD JD, CHERESH DA: Role of integrins in cell invasion and migration. Nat. Rev. Cancer (2002) 2:91-100.
57. GIANCOTTI FG, RUOSLAHTI E: Integrin signaling. Science (1999) 285:1028-32.
58. FELDING-HABERMANN B, O'TOOLE TE, SMITH JW et al.: Integrin activation controls metastasis in human breast cancer. Proc. Natl. Acad. Sci. USA (2001) 98:1853-1858.
59. PRUITT K, DER CJ: Ras and Rho regulation of the cell cycle and oncogenes. Cancer Lett. (2001) 171:1-10.
60. BAR-SAGI D: A Ras by any other name. Mol. Cell. Biol. (2001) 21:1441-1443.
61. BOS JL: Ras oncogenes in human cancer: a review. Cancer Res. (1989) 49:4682-4689.
62. MALANEY S, DALY RJ: The ras signaling pathway in mammary tumorigenesis and metastasis. J. Mammary Gland Biol. Neoplasia (2001) 6(1):101-113.
63. VARGHESE HJ, DAVIDSON MT, MACDONALD IC et al.: Activated Ras regulates the proliferation/apoptosis balance and early survival of developing micrometastasis. Cancer Res. (2001) 61:887-891.
64. SAHAI E, MARSHALL CJ: Rho-GTPases and cancer. Nat. Rev. Cancer (2002) 2:133-42.
65. MAREEL M, LEROY A: Clinical, cellular and molecular aspects of cancer invasion. Physiol. Rev. (2000) 83:337-376.
66. TAMANOI F, KATO-STANKIEWICZ J, JIANG C, MACHADO I, THAPAR N: Farnesylated proteins and cell cycle progression. J. Cell Biochem. (2001) 37(Suppl.):64-70.
67. MANNING G, WHYTE DB, MARTINEZ R, HUNTER T, SUDARSANAM S: The protein kinase complement of the human genome. Science (2002) 298:1912-1934.
68. MANNING BD, CANTLEY LC: Hitting the target: emerging technologies in the search for kinase substrates. Sci. STKE (2002) (162):PE49.
69. COLLETT MS, ERIKSON RL: Protein kinase activity associated with the avian sarcoma virus src gene product. Proc. Natl. Acad. Sci. USA (1978) 75:2021-2024.
70. STRAWN LM, SHAWVER LK: Tyrosine kinases in diseases. Overview of kinase inhibitors as therapeutic agents and current drugs in clinical trials. Expert Opin. Investig. Drugs (1998) 7:533-573.
71. TSATSANIS C, SPANDIDOS DA: The role of oncogenic kinases in human cancer. Int. J. Molec. Med. (2000) 5:583-590.
72. COHEN P: Protein kinases - the major drug targets of the twenty-first century? Nat. Rev. Drug Discov. (2002) 1:309-315.
73. DREVS J, MEDINGER M, SCHMIDT-GERSBACH C, WEBER R, UNGER C: Receptor tyrosine kinases: the main targets for new anticancer therapy. Curr. Drug Targets (2003) 4:113-121.
74. BRUNELLESCHI S, PENEGO L, SANTORO MM, GAUDINO G: Receptor tyrosine kinases as target for anti-cancer therapy. Curr. Pharm. Design (2002) 8:1959-1972.
75. FABBRO D, RUETZ S, BUCHDUNGER E et al.: Protein kinases as targets for anticancer agents: from inhibitors to useful drugs. Pharmacol. Ther. (2002) 93(2-3):79-98.
76. COHEN GB, REN R, BALTIMORE D: Modular binding domains in signal transduction. Cell (1995) 80:237-248.
77. PAWSON T: Protein modules and signalling networks. (1995) Nature 373:573-580.
78. SAWYER TK, BOHACEK RS, DALGARNO DC et al.: SRC homology-2 inhibitors: peptidomimetic and nonpeptide. Mini-Rev. Med. Chem. (2002) 2:475-488.
79. CIARDIELLO F, TORTORA G: A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res. (2001) 7:2958-2970.
80. MCLEAN GW, AVIZIENYTE E, FRAME MC: Focal adhesion kinase as a potential target in oncology. Expert Opin. Pharmacother. (2003) 4:227-234.
81. JONES RJ, BRUNTON VG, FRAME MC: Adhesion-linked kinases in cancer, emphasis on src, focal adhesion kinase and PI 3-kinase. Eur. J. Cancer (2000) 36:1595-1606.
82. SAWYER T, BOYCE B, DALGARNO, IULIUCCI J: Src inhibitors: genomics to therapeutics. Expert Opin. Investig. Drugs (2001) 10:1327-1344.
83. METCALF CA III, VAN SCHRAVENDIJK MR, DALGARNO DC, SAWYER TK: Targeting protein kinases for bone disease: discovery and development of Src inhibitors. Curr. Pharm. Design (2002) 8:2049-2075.
84. SUSA M, MISSBACH, M, GREEN J: Src inhibitors: drugs for the treatment of osteoporosis, cancer or both? Trends Pharmacol. Sci. (2000) 21:489-495.
85. MAA M-C, LEU TH, MCCARLEY DJ, SCHATZMAN RC, PARSONS SJ: Potentiation of epidermal growth factor receptor-mediated oncogenesis by c-Src: implications for the etiology of multiple human cancers. Proc. Natl. Acad. Sci. USA (1995) 92:6981-6985.
86. MAO W, IRBY R, COPPOLA D et al.: Activation of c-Src by receptor tyrosine kinases in human colon cancer cells with high metastatic potential. Oncogene (1997) 15:3083-3090.
87. IRBY RB, MAO W, COPPOLA D et al.: Activating SRC mutation in a subset of advanced human colon cancers. Nat. Genet. (1999) 21:187-190.
88. c-src in progressive stages of human colorectal cancer. J. Clin. Invest. (1993) 91:3-60.
89. VAN OIJEN MG, RIJKSEN G, TEN BROEK FW, SLOOTWEG PJ: Overexpression of c-Src in areas of hyperproliferation in head and neck cancer, premalignant lesions and benign mucosal disorders. J. Oral Pathol. Med. (1998) 27:147-152.
90. LUTZ MP, ESSE IBIB, FLOSSMANN-KAST BB et al.: Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma. Biochem. Biophys. Res. Commun. (1998) 243:503-508.
91. NABEL EG: CDKs and CKIs: molecular targets for tissue remodelling. Nat. Rev. Drug Discov. (2002) 1:587-598.
92. MORGA DO: Cyclin-dependent kinases: engines, clocks, and microprocessors. Ann. Rev. Cell. Dev. Biol. (1997) 13:261-291.
93. SIELECKI TM, BOYLAN JF, BENFIELD PA, TRAINOR GL: Cyclin-dependent kinase inhibitors: useful targets in cell cycle regulation. J. Med. Chem. (2000) 43:1-18.
94. KAMB A, GRUIS NA, WEAVER-FELDHAUS J et al.: A cell cycle regulator potentially involved in genesis of many tumor types. Science (1994) 264:436-440.
95. LI Q, ZHU GD: Targeting serine/threonine protein kinase B/Akt and cell-cycle checkpoint kinases for treating cancer. Curr. Topics Med. Chem. (2002) 2:939-971
96. HILL MM, HEMMINGS BA: Inhibition of protein kinase B/Akt. Implications for cancer therapy. Pharmacol. Ther. (2002) 93:243-251.
97. MAYO LD, DONNER DB: The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network. Trends Biochem. Sci. (2002) 27:462-467.
98. VIVANCO I, SAWYERS CL: The phosphoinositide 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer (2002) 2:489-501.
99. YOGANATHAN N, YEE A, ZHANG Z et al.: Integrin-linked kinase, a promising cancer therapeutic target: biochemical and biological properties. Pharmacol. Ther. (2002) 93:233-242.
100. LOS M, BUREK CJ, STROH C, BENEDYK K, HUG H, MACKIEWICZ A: Anticancer drugs of tomorrow: apoptotic pathways as targets for drug design. Drug Discov. Today (2003) 8:67-77.
101. STEIN RC: Prospects for phosphoinositide 3-kinase inhibition as a cancer treatment. Endocr. Relat. Cancer (2001) 8:237-248.
102. CHEN J, FANG Y: A novel pathway regulating the mammalian target of rapamycin (mTOR) signaling. Biochem. Pharmacol. (2002) 64:1071-1077.
103. HIDALGO M, ROWINSKI EK: The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene (2000)19:6680-6686.
104. HUANG S, HOUGHTON PJ: Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic. Curr. Opin. Investig. Drugs (2002) 3:295-304.
105. MAGEE T, MARSHALL C: New insights into the interaction of Ras with the plasma membrane. Cell (1999) 98:9-12.
106. KERKHOFF E, RAPP UR: Cell cycle targets of Ras/Raf signalling. Oncogene (1998) 17:1457-1462.
107. WEINSTEIN-OPPENHEIMER CR, BLALOCK WL, STEELMAN LS, CHANG F, MCCUBREY JA: The Raf signal transduction cascade as a target for chemotherapeutic intervention in growth factor-responsive tumors. Pharmacol Ther. (2000) 88:229-279.
108. NOTTAGE M, SIU LL: Rationale for Ras and raf-kinase as a target for cancer therapeutics. Curr. Pharm. Des. (2002) 8:2231-2242.
109. DAVIES H, BIGNELL GR, COX C et al.: Mutations of the BRAF gene in human cancer. Nature (2002) 417:949-954.
110. JOHNSON GL, LAPADAT R: Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science (2002) 298:1911-1912.
111. KATSANAKIS KD, OWEN C, ZOUMPOULIS V: JNK and ERK signaling pathways in multistage mouse carcinogenesis: studies in the inhibition of signaling cascades as a means to understand their in vivo biological role. Anticancer Res. (2002) 22:755-759.
112. FOLKMAN J: Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. (2000) 29:15-19.
113. RELF M, LEJEUNE S, SCOTT PA et al.: Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res. (1997) 57:963-969.
114. TAYLOR AP, OSORIO L, CRAIG R et al.: Tumor-specific regulation of angiogenic growth factors and their receptors during recovery from cytotoxic therapy. Clin. Cancer Res. (2002) 8:1213-1222.
115. NABESHIMA K, INOUE T, SHIMAO Y, SAMESHIMA T: Matrix metalloproteinases in tumor invasion: role for cell migration. Pathol. Intern. (2002) 52:255-264.
116. CHANG C, WERB Z: The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. Trends Cell. Biol. (2001) 11:S37-S43.
117. JIANG Y, GOLDBERG ID, SHI YE: Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene (2001) 21:2245-2252.
118. 4 integrins in tumor invasion. Clin. Exp. Metastasis (2002) 19:217-223.
119. 3 as a therapeutic target for blocking tumor-induced angiogenesis. Curr. Drug Targets (2003) 4:123-131.
120. ALBELDA SM, METTE SA, ELDER DE et al.: Integrin distribution in malignant melanoma: association of the β3 subunit with tumor progression. Cancer Res. (1990) 50:6757-6764.
121. 3 expression by bone-residing breast cancer metastases. Diagn. Mol. Pathol. (1996) 5:27-135.
122. 3 expression confers on tumor cells a greater propensity to metastasize to bone. FASEB J. (2002) 16:1266-1268.
123. 3 integrin in the development of osteolytic bone metastases: a pharmacological target for alternative therapy? Calcified Tissue Intern. (2002) 71:293-299.
124. TUCKER GC: Inhibitors of integrins. Curr. Opin. Pharmacol. (2002) 2:394-402.
125. COLEMAN RE: Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat. Rev. (2001) 27:165-176.
126. O'KEEFE, RJ, SCHWARZ EM, BOYCE BF: Bone metastasis: an update on mechanisms of bone resorption and therapeutic strategies. Curr. Opin. Orthoped. (2000) 11:353-359.
127. SOUTHBY J, KISSIN MW, DANKS JA et al.: Immunohistochemical localization of parathyroid hormone-related protein in breast cancer. Cancer Res. (1990) 50:7710-7716.
128. POWELL GJ, SOUTHBY J, DANKS JA et al.: Localization of parathyroid hormone-related protein in breast cancer metastasis: increased incidence in bone compared to other sites. Cancer Res. (1991) 51:3059-3061.
129. BRYDEN AA, HOYLAND JA, FREEMONT AJ, CLARKE NW, GEORGE NJ: Parathyroid hormone related peptide and receptor expression in paired primary prostate cancer and bone metastasis. Br. J. Cancer (2002) 86:322-325.
130. MIKI T, YANO S, HANBUCHI M, SONE S: Bone metastasis model with multiorgan dissemination of human small-cell lung cancer. Oncol. Res. (2001) 12:209-217.
131. ZHANG QX, BORG A, WOLF DM, OESTERREICH S, FUQUA SA: An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer. Cancer Res. (1997) 57:1244-1249.
132. DE LARCO JE, WUERTZ BR, ROSNER KA al.: A potential role for IL-8 in the metastatic phenotype of breast carcinoma cells. Am.. J. Pathol. (2001) 158:639-646.
133. DOWNEY SE, HOYLAND J, FREEMONT AJ, KNOX F, WALLS J, BRUNDRED NJ: Expression of the receptor for parathyroid hormone-related protein in normal and malignant breast tissue. J. Pathol. (1997) 183:212-217.
134. GUISE TA, YIN JJ, TAYLOR SD et al.: Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J. Clin. Invest. (1996) 98:1544-1549.
135. GALLWITZ WE, GUISE TA, MUNDY GR: Guanosine nucleotides inhibit different syndromes of PTHrP excess caused by human cancers in vivo. J. Clin. Invest. (2002) 110:1559-1572.
136. BENDRE MS, GADDY-KURTEN D, MON-FOOTE T et al.: Expression of interleukin 8 and not parathyroid hormone-related protein by human breast cancer cells correlates with bone metastasis in vivo. Cancer Res. (2002) 62:5571-5579.
137. THOMAS RJ, GUISE TA, YIN JJ et al.: Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology (1999) 140:4451-4458.
138. NELSON JB, NABULISI AA, VOGELZANG NJ et al.: Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat. Med. (1995) 1:944-949.
139. GUISE TA, YIN JJ, MOHAMMED KS: Role of endothelin-1 in osteoblastic bone metastases. Cancer (2003) 97:779-784.
140. HARRIS SE, BONEWALD LF, HARRIS MA et al.: Effects of transforming growth factor-β on bone nodule formation and expression of bone morphogenic protein 2, osteocalcin, osteopontin, alkaline phosphatase, and type 1 collagen mRNA in longterm cultures of fetal rat calvarial osteoblasts. J. Bone Min. Res. (1994) 9:855-863.
141. DAWSON NA. Bisphosphonates: their evolving role in the management of prostate cancer-related bone disease. Curr. Opin. Urol. (2002) 12:413-418.
142. GREEN JR, CLEZARDIN P: Mechanisms of bisphosphonate effects on osteoclasts, tumor cell growth, and metastasis. Am. J. Clin. Oncol. (2002) 25(6 Suppl. 1):S3-S9.
143. SASAKI A, BOYCE BF, STORY B et al.: Bisphosphonate risedronate reduces metastatic human breast cancer burden in nude mice. Cancer Res. (1995) 55:3551-3557.
144. DIEL IF, SOLOMAYER EF, COSTA SD et al.: Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N. Engl. J. Med. (1998) 339:357-363.
145. CARTER P: Improving the efficacy of antibody-based cancer therapies. Nat. Rev. Cancer (2001) 1:118-129.
146. ELLIS LM: A targeted approach for antiangiogenic therapy of metastatic human colon cancer. Am. Surg. (2003) 69:3-10.
147. LEYLAND-JONES B: Trastuzumab: hopes and realities. Lancet Oncol. (2002) 3:137-144.
148. GRETEN TF, JAFFEE EM: Cancer vaccines. J. Clin. Oncol. (1999) 17:1047-1060.
149. TAMM I, KORKEN B, HARTMANN G: Antisense therapy in oncology: new hope for an old idea? Lancet (2001) 358:489-497.
150. WANG H, PRASAD G, BUOLAMWINI JK, ZHANG R: Antisense anticancer oligonucleotide therapeutics. Curr. Cancer Drug Targets (2001) 1:177-196.
151. MCCORMICK F: Cancer gene therapy: fringe or cutting edge? Nat. Rev. Cancer (2001) 1:130-141.
152. BYKOV FJN, ISSAEVA N, SHILOV A et al.: Restoration of tumor suppressor function to mutant p53 by a low-molecular weight compound. Nat. Med. (2002) 8:282-288.
153. AINA OH, SROKA TC, CHEN ML, LAM KS: Therapeutic cancer targeting peptides. Biopolymers (2002) 66:184-199.
154. BRUMMELKAMP TR, BERNARDS R: New tools for functional mammalian cancer genetics. Nat. Rev. Cancer (2003) 3:781-788.
155. ANZICK SL, TRENT JM: Role of genomics in identifying new targets for cancer therapy. Oncology (2002) 16(5 Suppl. 4):7-13.
156. HANASH S: Disease proteomics. Nature (2003) 422:226-232.
157. DANCEY J, SAUSVILLE EA: Issues and progress with protein kinase inhibitors for cancer treatment Nat. Rev. Drug Discov. (2003) 2:296-313.
158. FABBRO D, RUETZ S, BUCHDUNGER E et al.: Protein kinases as targets for anticancer agents: from inhibitors to useful drugs. Pharmacol. Ther. (2002) 93:79-98.
159. DE BONO JS, ROWINSKY EK: Therapeutics targeting signal transduction for patients with colorectal carcinoma. Br. Med. Bull. (2002) 64:227-254.
160. ZHU Z, BOHLEN P, WITTE L: Clinical development of angiogenesis inhibitors to vascular endothelial growth factor and its receptors as cancer therapeutics. Curr. Cancer Drug Targets (2002) 2:135-156.
161. BASELGA J, HAMMOND LA: HER-targeted tyrosine-kinase inhibitors. Oncology (2002) 63(Suppl. 1):6-16.
162. RANSON M, SLIWKOWSKI MX: Perspectives on anti-HER monoclonal antibodies. Oncology (2002) 63(Suppl. 1):17-24.
163. LIPTON A, SMALL E, SAAD F et al.: The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. Cancer Invest. (2002) 20(Suppl. 2):45-54.
164. LIPTON A: Bone metastases in breast cancer. Curr. Treat. Options Oncol. (2003) 4:151-158.
165. GIANNI L: The future of targeted therapy: combining novel agents. Oncology (2002) 63(Suppl. 1):47-56.
166. HALUSKA P, DY GK, ADJEI AA: Farnesyl transferase inhibitors as anticancer agents. Eur. J. Cancer (2002) 38:1685-1700.
167. OHKANDA J, KNOWLES DB, BLASKOVICH MA, SEBTI SM, HAMILTON AD: Inhibitors of protein farnesyltransferase as novel anticancer agents. Curr. Top. Med. Chem. (2002) 2:303-323
168. JOHNSTON SR: Farnesyl transferase inhibitors: a novel targeted therapy for cancer. Lancet Oncol. (2001) 2:18-26.
169. SEBOLT-LEOPOLD JS: Development of anticancer drugs targeting the MAP kinase pathway. Oncogene (2000) 19:6594-6599.
170. HIRTE HW, VERGOTE IB, JEFFREY JR et al.: An international multicentre Phase III study of BAY 12-9566 (BAY) versus placebo in patients (pts) with advanced ovarian cancer (OVCA) responsive to primary surgery/paclitaxel + platinum containing chemotherapy. Proc. Am. Soc. Clin. Oncol. (2001) 20:A843 (Abstract).
171. EGEBLAD M, WERB Z: New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer (2002) 2:161-174.
172. SPARANO JP, BERNARDO P, GRADISHAR WJ, INGLE JN, ZUCKER S, DAVIDSON NE: Randomized Phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: an Eastern Cooperative Oncology Group trial. Proc. Am. Soc. Clin. Oncol. (2002) 21:A173 (Abstract).
173. KING J, CLINGAN P, MORRIS DL: Placebo control double-blind randomised clinical trial of the matrix metalloproteinase inhibitor (MMP) marimastat in patients with inoperable colorectal cancer liver metastasis (CRCLM): significant survival advantage in patients with muscoloskeletal symptoms. Proc. Am. Soc. Clin. Oncol. (2002) 21:A537 (Abstract).
174. BRAMHALL SR, ROSEMURGY A, BROWN PD, BOWRY C, BUCKELS JAC: Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J. Clin. Oncol. (2001) 19:2447-3455.
175. YANG JC, HAWORTH I, STEINBERG SM, ROSENBERG SA, NOVOTNY W: A randomized double-blind placebo-controlled trial of bevacizumab (anti-VEGF antibody) demonstrating a prolongation in time to progression in patients with metastatic renal cancer. Proc. Am. Soc. Clin. Oncol. (2002) 21:A15 (Abstract).
176. 3. Clin. Cancer Res. (2000) 6:3056-3061.
177. VOEST EE, BEEREPOOT LV, GROENEWEGAN G et al.: Phase I trial of recombinant angiostatin by twice-daily subcutaneous injection in patients with advanced cancer. Proc. Am. Soc. Clin. Oncol. (2002) 21:A322 (Abstract).
178. HERBST RS, HESS KR, TRAN HT et al.: Phase I study of recombinant human endostatin in patients with advanced solid tumors. J. Clin. Oncol. (2002) 20:3792-3803.
179. POWLES T, PATERSON S, KANIS JA et al.: Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J. Clin. Oncol. (2002) 20:3124-3219.
180. FREIJE JM, BALBIN M, PENDAS AM, SANCHEZ LM, PUENTE XS, LOPEXZ-OTIN C: Matrix metalloproteinases and tumor progression. Adv. Exp. Med. Biol. (2003) 532:91-107.
181. HEIKKILA P, TERONEN O, HIRU MY et al.: Inhibition of matrix metalloproteinase-14 in osteosarcoma cells by clodronate. J. Surg. Res. (2003) 111:45-52.
182. CLEZARDIN P, FOURNIER P, BOISSIER S, PEYRUCHAUD O: In vitro and in vivo antitumor effects of bisphosphonates. Curr. Med. Chem. (2003) 10:173-180.
183. OADES GM, SENARTNE SG, CLARKE IA, KIRBY RS, COLSTON KW: Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevolonate pathway, impairing Ras membrane localization. J. Urol. (2003) 170:246-252.
184. DENOYELLE C, HONG L, VANNIER JP, SORIA C: New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and independent effects. Br. J. Cancer (2003) 88:1631-1640.
185. DRUKER BJ: STI571 (Gleevec/Glivec, imatinib) versus interferon + cytarabine as initial therapy for patients with CML. Results of a randomized study. Proc. Am. Soc. Clin. Oncol. (2002) 21:A1.
186. CAPDEVILLE R, BUCHDUNGER E, ZIMMERMANN J, MATTER A: Glivec (STI571, Imatinib), a rationally developed, targeted anticancer drug. Nat. Rev. Drug Disc. (2002) 1:493-502.
187. BASELGA J, TRIGO JM, BOUHRIS J et al.: Cetuximab (C225) plus cisplatin/carboplatin is active in patients (Pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) progressing on a same does and schedule platinum-based regimen. Proc. Am. Soc. Clin. Oncol. (2002) 21-A900 (Abstract).
188. BURTNESS BA, FLOOD YLW, MATTAR BI, FORASTIERE AA: Phase III trial comparing cisplatin (C) + placebo (P) + epidermal growth factor receptor antibody (EGF-R) C225 in patients (pts) with metastatic/recurrent head and neck cancer (HNC). Proc. Am. Soc. Clin. Oncol. (2000) 21:A901 (Abstract).
189. SLAMON DJ, LEYLAND-JONES B, SHAK S et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. (2001) 344:783-792.
190. FUKUOKA M, YANO S, GIACCONE G et al.: Final results from a Phase II trial of ZD1839 ('Iressa') for patients with advanced non-small cell lung cancer (IDEAL1). Proc. Am. Soc. Clin. Oncol. (2002) 21:A1188 (Abstract).
191. NATALE RB, SKARIN A, MADDOX AM et al.: Improvement in symptoms and quality of life from advanced non-small cell lung cancer patients receiving ZD1839 ('Iressa') in IDEAL 2. Proc. Am. Soc. Clin. Oncol. (2002) 21:A1167 (Abstract).
192. WILKINSON E: Surprise Phase III failure for ZD1839. Lancet Oncol. (2002) 3:583.
193. HIDALGO M, SIU LL, NEMUNAITIS J et al: Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J. Clin. Oncol. (2001) 19:3267-3279.
194. SUMMY JM, GALLICK GE: Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev. (2003) 22:337-358.
195. WANG Y, METCALF CA III, SHAKESPEARE WC et al.: Bone-targeted 2,6,9-trisubstituted purines: novel inhibitors of Src tyrosine kinase for the treatment of bone diseases. Bioorg. Med. Chem. Lett. (2003) 13:3067-3070.
196. SUNDARAMOORTHI R, SHAKESPEARE WC, KEENAN TP et al.: Bone-targeted Src kinase inhibitors: novel pyrrolo- and pyrazolopyrimidine analogs. Bioorg. Med. Chem. Lett. (2003) 13:3063-3066.
197. VU C, LUKE GP, KAWAHATA N et al.: Bone-targeted pyrido[2,3-d]pyrimidin-7-ones: potent inhibitors of Src tyrosine kinase as novel antiresorptive agents. Bioorg. Med. Chem. Lett. (2003) 13:3071-3074.
198. BOYCE BF, XING L, SHAKESPEARE W et al.: Regulation of bone remodeling and emerging breakthrough drugs for osteoporosis and osteolytic bone metastases. Kidney Int. (2003) 85:52-55.
199. SHAKESPEARE W, WANG Y, METCALF C et al.: Development of a novel bone-targeted Src tyrosine kinase inhibitor AP23451 having potent activity in an animal model of osteolytic bone metastasis. Proc. Am. Acad. Cancer Res. (2003) 44:A3871 (Abstract).
200. BELSCHES-JABLONSKI AP, BISCARDI JS, PEAVY DR, TICE DA ROMNEY DA, PARSONS SJ: Src family kinases and HER2 interactions in human breast cancer cell growth and survival. Oncogene (2001) 20:14674-1475.
201. MENKE A, PHILIPP C, VOGELMANN R et al.: Down-regulation of E-cadherin gene expression by collagen type I and type II in pancreatic cell lines. Cancer Res. (2001) 61:3508-3517.
202. ELICEIRI BP, PAUL R, SCHWARTBERG PL, HOOD JD, LENG J, CHERESH DA: Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol. Cell (1999) 4:915-924.
203. TATTON L, MORLEY GM, CHOPRA R, KHWAJA A: The Src-selective kinase inhibitor PP1 also inhibits Kit and Bcr-Abl tyrosine kinases. J. Biol. Chem. (2003) 278:4847-4853.
204. CARLOMAGNO F, VITAGLIANO D, GUIDA T et al.: The kinase inhibitor PP1 blocks tumorogenesis induced by RET oncogenes. Cancer Res. (2002) 62:1077-1082.
205. NAM JS, INO Y, SAKAMOTO M, HIROHASHI S: Src family kinase inhibitor PP2 restores the E-cadherin/catenin cell adhesion system in human cancer cells and reduces cancer metastasis. Clin. Cancer Res. (2002) 8:2430-2436.
206. BOSCHELLI DH: 4-Anilino-3-quinolinecarbonitriles: an emerging class of kinase inhibitors. Curr. Top. Med. Chem. (2002) 2:1051-1063.
207. YEZHELYEV M, WAGNER C, KOHL G et al.: In vivo and in vitro effects of a novel Src tyrosine kinase inhibitor on human pancreatic cancer in a nude mouse model. Proc. Am. Acad. Cancer Res. (2003) 44:A1718 (Abstract).
208. KEKHARAM M, NASIR A, KAISER HE, COPPOLA D: Insulin-like growth factor-1 receptor activates c-SRC and modifies transformation and motility of colon cancer in vitro. Anticancer Res. (2003) 23:1517-1524.
209. RECCHIA I, RUCCI N, FESTUCCIA C et al.: Pyrrolopyrimidine c-Src inhibitors reduce growth, adhesion, motility and invasion of prostate cancer cells in vitro. Eur. J. Cancer (2003) 39:1927-935.
210. METCALF C III, WANG Y, SHAKESPEARE W et al.: Discovery of potent and selective Src inhibitors and their development as antitumor and antimetastatic agents. Proc. Am. Acad. Cancer Res. (2003) 44:A1716.
211. O'HARE T, STOFFREGEN EP, ABDULLAH OM et al.: Potent inhibition of Imatinib-resistant variants of Bcr-Abl by a novel dual selective Src/Abl kinase inhibitor AP23464: Implications for CML therapy. Proc. Am. Soc. Hematol. (2003) A59.